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Abstract:  
Objective: Obesity negatively affects human health. Limiting food intake, while producing some weight loss, results in 
reduction of lean body mass. Combined with moderate exercise it produces significant weight loss, maintains lean body 
mass and improves insulin sensitivity, but appears difficult to adhere to. Bariatric surgery is clinically effective for se-
verely obese individuals compared with non-surgical interventions, but has limitations. Clinical and pre-clinical studies 
have implicated a role for testosterone (T) in the patho-physiology of obesity.  
Methods: Evidence Acquisition and Synthesis: A literature search in PubMed on the role of T in counteracting obesity and 
its complications.  
Results: Obesity per se impairs testicular T biosynthesis. Furthermore, lower-than-normal T levels increase accumulation 
of fat depots, particularly abdominal (visceral) fat. This fat distribution is associated with development of metabolic syn-
drome (MetS) and its sequels, namely type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). T treatment 
reverses fat accumulation with significant improvement in lean body mass, insulin sensitivity and biochemical profiles of 
cardiovascular risk. The contribution of T to combating obesity in hypogonadal men remains largely unknown to medical 
professionals managing patients with obesity and metabolic syndrome. Many physicians associate T treatment in men 
with risks for prostate malignancy and CVD. These beliefs are not supported by recent insights.  
Conclusion: While overall treatment of obesity is unsuccessful, T treatment of hypogonadal men may be effective, also 
because it improves mood, energy, reduces fatigue and may motivate men to adhere to diet and exercise regimens de-
signed to combat obesity.  
Keywords: Obesity, metabolic syndrome, testosterone, diabetes mellitus, weight reduction, drug safety. 
INTRODUCTION 
Obesity is reaching epidemic proportions worldwide with 
profound impact on health resulting in reduced quality of 
life, early death. If obesity will continue to rise, it will un-
doubtedly increase health care costs and impede economic 
progress and national well being of many countries [1, 2]. 
Deposition of excess fatty acids (FAs) into fat cells in the 
form of triglycerides (TGs) is the biochemical basis of obe-
sity, thus any imbalance in food intake and energy utilization 
may result in obesity. This homeostasis is complex and is 
regulated by a host of metabolic and endocrine factors which 
are poorly understood. Obesity contributes to pathologies, 
such as the metabolic syndrome (MetS), cardiovascular dis-
ease (CVD), type 2 diabetes mellitus (T2DM), hypertension, 
endothelial dysfunction [ED] and testosterone deficiency 
(hypogonadism) [TD]. Obese individuals often exhibit char- 
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acteristics of MetS [3] with increased body mass index 
(BMI), waist circumference (WC) and waist-to-hip ratio 
(WHR).  
Differences in gender distribution of body fat are well 
recognized [4] and in men, fat accumulates in the abdominal 
regions (both subcutaneous and intra-abdominal or visceral 
fat depots) and generally exhibits larger visceral fat depot 
relative to (premenopausal) women [5, 6]. In premenopausal 
women, a larger proportion of fat is stored in peripheral fat 
depots such as breasts, hips and thighs. Not surprisingly, sex 
steroids have been shown to contribute to this sex difference. 
Fat distribution (a large visceral fat depot) is a strong predic-
tor of CVD and of the development of T2DM, and is also 
linked to a negative biochemical cardiovascular risk profile 
[7].  
ROLE OF TESTOSTERONE IN ETIOLOGY, PATHO-
PHYSIOLOGY AND TREATMENT OF MALE OBE-
SITY  
In addition to its role as a critical steroid hormone in re-
productive and sexual functioning, T is an important signal-
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ing molecule in regulating energy utilization and multiple 
cellular metabolic pathways, including nitrogen retention 
and regulation of adipogenesis [3, 8, 9]. Considerable evi-
dence exists with regard to the role of T in increasing and 
maintaining muscle mass and reducing fat mass and there-
fore regulation of body composition [10]. This suggests that 
TD may contribute to the etiology of obesity and, in case of 
hypogonadism, T treatment may turn out to be beneficial in 
managing obesity, also in combination with exercise and diet 
[11, 12]. As shown in Fig. (1), testosterone treatment im-
proves body composition. The potential of testosterone to 
improve the metabolic situation in hypogonadal has met with 
reservation. For many decades, T was perceived by the 
medical community to play a role in the development of 
prostate cancer (PCa) [13], and was thought of as a risk fac-
tor for CVD [14]. The higher prevalence of coronary heart 
disease in men, compared with women, was attributed to T, 
being the most obvious gender difference. Recent clinical 
studies have proven both assumptions inaccurate. There is no 
compelling evidence that T is a significant factor in the eti-
ology of CVD [14] and of PCa [13], but once these unwar-
ranted perceptions had become common they are difficult to 
discredit. In this review, we summarize the role of T in the 
etiology and treatment of obesity in men with TD from three 
perspectives: 1) evidence from epidemiological and observa-
tional studies, 2) evidence from androgen deprivation ther-
apy (ADT), mainly in men undergoing treatment for PCa, 
and 3) evidence from T treatment of men with TD. Rather 
than to advocate testosterone in the large field of anti-obesity 
treatment, the aim is to define more precisely a role for tes-
tosterone in the treatment of obesity and its associated condi-
tions in men with TD which has so far not received serious 
consideration. Naturally, the potential benefits must be bal-
anced against its (long-term) risks. 
RELATIONSHIP BETWEEN TESTOSTERONE AND 
OBESITY 
TD (hypogonadism) in men is defined as a serum T less 
than 12 nmol/L [15] combined with a set of clinical signs 
and symptoms, as outlined by several professional societies 
[16]. Several studies have demonstrated an inverse relation-
ship between indicators of obesity (body mass index, waist 
circumference, a reliable indicator of visceral obesity), and T 
levels over all age groups [3, 17, 18]. Obesity contributes to 
onset of T2DM, dyslipidemia, hypertension and, therefore, 
MetS. An inverse association between the severity of fea-
tures of MetS, T2DM and plasma T has been previously re-
ported [19]. In one study, this association was independent 
of age and body mass index [20], underlining the complexity 
of the relationship between testosterone and obesity [21]. 
This became also apparent from another study that verified 
the prevalence of low testosterone levels in male T2DM pa-
tients, related to variations in BMI, waist circumference, 
neuropathy, triglycerides, CRP, glucose, insulin and HOMA-
IR, but no increase of silent myocardial ischemia or periph-
eral arterial disease was established [22]. This is supported 
by other studies linking low testosterone, cardiovascular risk 
and insulin resistance (for review [23]).  
Although age is associated with the prevalence of MetS, 
young men with features of the MetS exhibit reduced T lev-
els [24, 25] and T treatment in these individuals positively 
affects weight reduction, with concomitant reduction in insu-
lin resistance (IR). The exact pathophysiological mecha-
nisms responsible for reduced T levels in obesity remain 
under investigation [3], however, hyperinsulinemia is shown 
to suppress serum T levels [26]. T levels are reduced in men 
with T2DM [17], with an inverse association between T lev-
els and glycosylated hemoglobin (HbA1c) [27] and this oc-
 
Fig. (1). 1 year testosterone therapy with parenteral testosterone undecanoate improves body composition in elderly men. Adapted from ref-
erence [71]. 
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curs independently of medications, such as statins [28]. In 
men with low plasma T, the likelihood of T2DM is increased 
and several large prospective studies have shown that low T 
levels predict development of T2DM in men. Low levels of 
T are associated with a decreased lean body mass, and rela-
tive muscle mass is inversely associated with insulin resis-
tance and prediabetes [29]. Epidemiological evidence from 
several longitudinal population studies shows that low T is 
an independent risk factor for the development of both MetS 
and T2DM [17, 28, 30], stroke or transient ischemic attacks 
[31]. A systematic review and meta-analysis of cross-
sectional studies indicated that T level was significantly 
lower in men with T2DM (mean difference, -76.6 ng/dL, 
95% confidence interval [CI], -99.4 to -53.6). Prospective 
studies have shown that men with higher T levels (range, 
449.6-605.2 ng/dL) had a 42% lower risk of T2DM (RR, 
0.58, 95% CI, 0.39 to 0.87). Reduced levels of total T and 
sex hormone binding globulin (SHBG) (associated with IR) 
were both independent risk factors in middle-aged men who 
later developed T2DM, according to The Massachusetts 
Male Aging Study (MMAS) and the Multiple Risk Factor 
Intervention Trial (MRFIT) [32, 33]. 
In The Rancho-Bernardo Study, a significant inverse cor-
relation was demonstrated between baseline total T, with 
long-term (8-year follow-up) fasting glucose and insulin 
levels as well as glucose intolerance [34]. In men, endoge-
nous testosterone concentrations were inversely related to 
mortality due to cardiovascular disease and all causes [35]. 
The authors concluded that low testosterone may be a predic-
tive marker for those at high risk of cardiovascular disease. 
The Tromso study nuanced these observations [36]. In this 
study, there was a significant increase in all-cause mortality 
risk for men with free testosterone in the lowest quartile 
(<158 pmol/L) compared with the higher quartiles after age 
adjustment hazard ratios (HR 1.24, 95% confidence interval, 
CI 1.01-1.53) and after multivariate adjustments (HR 1.24, 
95% CI 1.01-1.54). Total testosterone was not associated 
with mortality risk. Likewise, there were no significant 
changes in risk for first-ever MI across different total or free 
testosterone levels. Men with free testosterone levels in the 
lowest quartile had a 24% increased risk of all-cause mortal-
ity. 
Recently, the Third National Health and Nutrition survey 
(NHANES III) in a population of 1,413 men after adjustment 
for age, race/ethnicity and adiposity, showed that those men 
initially in the lowest tertile of either free or bioavailable (but 
not total) T were approximately four times more likely to 
have T2DM compared to those in the third tertile [37]. Col-
lectively, these findings support those reported by the 
MMAS in that the risk is independent of adiposity [17, 30, 
31]. In a recent review and meta-analysis of endogenous 
testosterone and mortality in men, Araujo et al. concluded 
that low endogenous testosterone levels are associated with 
increased risk of all-cause and cardiovascular death in com-
munity-based studies of men, but with considerable between-
study heterogeneity, which was related to study and subject 
characteristics, which suggests that effects are driven by dif-
ferences between cohorts (e.g. in underlying health status) 
[38]. 
THE VICIOUS CIRCLE OF LOW TESTOSTERONE 
AND OBESITY 
Synthesis of SHBG and T is a highly correlative bio-
chemical process. Hyperinsulinism, associated with adipos-
ity, suppresses synthesis of SHBG and thus, levels of circu-
lating T [39, 40]. In addition, insulin [41] and leptin [42] 
exert suppressive effects on testicular steroidogenesis and 
may contribute to further disruption of pulse amplitude of 
luteinizing hormone (LH) diminishing stimulation of the 
testicular steroidogenesis. Further, conversion of T to estra-
diol in adipose tissue resulting in elevated serum estradiol, 
may contribute to inhibition of androgen biosynthesis via 
central feedback mechanism involving the hypothalamus -
pituitary gonadal axis [43]. It is well recognized that adipo-
cytes secrete a host of adipokines that regulate a variety of 
metabolic processes in endocrine, paracrine and autocrine 
fashion. Thus, adipocytokines, secreted by visceral fat modu-
late the hypothalamo-pituitary-testicular axis and inhibit T 
production [44]. Modulation of GnRH secretion by Kisspept-
ins, produced by adipose tissue causes significant lowering 
circulating levels of T [45]. Clear and illustrative clinical 
examples for a role of T in the onset of MetS are demon-
strated in patients with PCa undergoing ADT or in men with 
T2DM. This treatment is accompanied with decreased total 
lean body mass, increased total fat mass, and, particularly in 
the longer-term, the development of the MetS. More impor-
tantly, acute ADT reduces insulin sensitivity and strongly 
impairs glycemic control of men with T2DM [46, 47]. Thus, 
a vicious circle ensues in which MetS suppresses T biosyn-
thesis and conversely, reduced T concentrations predispose 
and contribute to the onset of development of MetS [32] and 
in turn obesity. 
OBESITY, LOW TESTOSTERONE AND INFLAM-
MATION 
Visceral obesity is associated with insulin resistance (IR), 
hyperglycemia, atherogenic dyslipidemia, hypertension as 
well as pro-thrombotic and pro-inflammatory states. Adipose 
tissue is presently considered as an endocrine organ secreting 
various biochemical factors known as adipokines. The adi-
pokines act via paracrine, autocrine and endocrine fashion 
influencing the metabolism of lipid, glucose homeostasis, 
and may influence cardiovascular risk factors, such as hyper-
tension, as well as thrombotic and inflammatory processes. 
Tumor
 necrosis factor-alpha (TNF-) and interleukin (IL)-6 
are inflammatory markers secreted by adipocytes and con-
tribute to the development of IR [48]. Reduced sex hormone 
levels are associated with increased inflammatory markers 
[49-51]. In elderly men, an inverse relationship between 
plasma T and inflammatory markers was observed [49]. 
Acute withdrawal of T in young, otherwise healthy hypogo-
nadal patients, caused significant increases in IL-6 and TNF-
 two weeks after cessation of T treatment. T treatment in 
men with lower-than-normal serum T produces reduction in 
adipokines [50], though these are not observed in a short 
(three-month) study [51]. Whether the effect of T is via inhi-
bition of differentiation of pluripotent cells into adipocytes 
or proliferation of pre-adipocytes, thus favoring myogenic 
differentiation [8] remains to be established. In short term 
studies, (< 3 months) T administration suppressed adi-
ponectin levels [52] with a potentially adverse effect on 134    Current Diabetes Reviews, 2012, Vol. 8, No. 2  Saad et al. 
 
CVD risk. In patients with newly diagnosed T2DM, T treat-
ment for one year was associated with an improvement of 
body composition and increased adiponectin levels [12] (Fig. 
2). 
REDUCTION OF AGE-RELATED DECLINE IN TES-
TOSTERONE 
The age-related changes in neuroendocrine function di-
minish the efficacy of luteinizing hormone in stimulating 
Leydig cells [40]. An increasing body of evidence suggests 
that disease significantly contributes to the age-related de-
cline of T [44, 53]. As shown in Fig. (2), changes in lifestyle 
(diet / exercise), leading to weight loss, might partially pre-
vent or redress decline of androgen levels with aging [12]. 
Also Roux-en-Y gastric bypass surgery reduced body mass 
index and increased total and free T levels [54]. Apparently, 
body fat mass possesses the potential to lower serum T, re-
versible upon weight loss. 
TESTOSTERONE, ADIPOSE TISSUE AND LIPID 
METABOLISM  
Sex steroid hormones play an integral role in regulating 
cellular metabolism, accumulation and distribution of adi-
pose tissues. Estrogens, progesterone and androgen receptors 
are expressed in adipose tissues. Sex steroid hormones regu-
late the function of adipose tissues by genomic and non-
genomic signaling mechanisms. Activation of the cAMP 
cascade by sex steroid hormones would activate hormone-
sensitive lipase leading to lipolysis in adipose tissues. Their 
activation appears to be involved in the control of pre-
adipocyte proliferation and differentiation. T regulates line-
age determination in mesenchymal pluripotent cells by pro-
moting the myogenic lineage and inhibiting the adipogenic 
lineage [8]. T inhibits triglyceride uptake and lipoprotein 
lipase activity and causes a more rapid turnover of triglyc-
erides in subcutaneous abdominal adipose tissue and less in 
femoral fat and, maybe, mobilizes lipids from the visceral fat 
depot [55]. 
TREATMENT OF OBESE MEN WITH TESTOSTER-
ONE: EFFECTS ON BODY COMPOSITION 
T is an important factor in the etiology of obesity, MetS 
and its associated diseases T2DM and atherosclerotic dis-
ease. The question arises whether T treatment in obesity and 
MetS and its sequels, such as T2DM and CVD is beneficial. 
There is increasing body of evidence indicating a beneficial 
effect of T treatment on visceral fat and other components of 
the MetS [56]. As shown in Tables 1 and 2, T administration 
improves many parameters associated with obesity and ef-
fects on lean body mass. 
Changes in visceral fat appear to be related to changes in 
serum total T [57]. A number of randomized controlled trials 
have confirmed the beneficial effects of T on body composi-
tion and variables of the MetS. In a study of weekly admini-
stration of T enanthate 100 mg i.m., there was a significant 
increase in lean body mass, with a mean change in fat mass 
of 0.2 kg (n.s), and a decline of serum cholesterol. In an 
eight months study of 23 middle aged abdominally obese 
men, a decrease of visceral fat mass (without a change in 
body mass, subcutaneous fat mass or lean body mass) was 
observed. The net change of fat mass was -1.8 kg (-6.3%) 
(n.s.). IR improved and blood glucose, diastolic blood pres-
sure and serum cholesterol decreased with T treatment [58]. 
In a study of 108 men over 65 years of age fat mass de-
creased (-2.9 kg, -11.9%; (p<0.001)) and lean mass increased 
subsequent to T treatment [59]. Similar results were obtained 
in other studies [60-68]. In a study of 70 men over 36 
months, T treatment increased lean body mass, decreased fat 
mass (-4.5 kg; -16%), decreased total cholesterol, low-
density lipoprotein, and leptin [69]. A reduction in leptin and  
 
Fig. (2). Waist circumference in 32 men with newly diagnosed type 2 diabetes in the DIMALITE (Diabetes Management by Lifestyle and 
Testosterone) study. Adapted from reference [12]. 
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Table 1. Changes in Parameters of Obesity Upon Testosterone (T) Treatment Versus Placebo (Plc). 
 
Reference / Parameter  Preparation 
Treatment 
Duration 
Change T  Change Plc  Net Change 
Total fat mass (kg) 
Marin 1993 [58]  Gel   9 mo  -1.8  0.6  -2.4 
Snyder 1999 [59]  Patch   36 mo  -3.3  -1.3  -2.0 
Kenny 2001 [62]  Patch   12 mo  -1.7  0.3  -1.4 
Ferrando 2002 [63]  TE  6 mo  -3.6  0.3  -3.9 
Boyanov 2003 [64]  Oral TU   3 mo  -1.65  -0.25  -1.4 
Crawford 2003 [65]  Mixed esters  12 mo  -2.3  0.7  -3.0 
Steidle 2003 [66]  Gel  3 mo  -0.8  -0.1  -0.7 
Steidle 2003 [66]  Patch   3 mo  -0.4  -0.1  -0.3 
Wittert 2003 [61]  Oral TU   12 mo  -0.2  0.85  -1.05 
Casaburi 2004 [67] (no tr.)  TE   10 wk  -1.01  -0.08  -0.93 
Casaburi 2004 [67] (training)  TE  10 wk  -1.41  -0.13  -1.28 
Svartberg 2008 [71]  Inj TU  12 mo  -5.4  -0.6  -4.8 
Allan 2008 [57]  Patch   12 mo  -0.5  0.1  -0.6 
Emmelot-Vonk 2008 [10]  Oral TU   6 mo  -1.0  -0.1  -0.9 
Srinivas-Shankar 2010 [68]  Gel   6 mo  -0.8  -0.3  -0.5 
Visceral adipose tissue (kg) 
Marin 1993 [58]  Gel  9 mo  -0.6  0.2  -0.8 
Allan 2008 [57]  Patch  12 mo  -0.2  0.5  -0.7 
Trunk fat (kg) 
Casaburi 2004 [67] (no tr.)  TE   10 wk  -0.55  0.34  -0.89 
Casaburi 2004 [67] (training)  TE  10 wk  -0.67  0.11  -0.78 
Page 2005 [69]  TE  36 mo  -1.9  -0.4  -1.5 
Allan 2008 [57]  Patch  12 mo  0.1  0.0  0.1 
Visceral adipose tissue (cm
3) 
Svartberg 2008 [71]  Inj TU  12 mo  -38  -11  -27 
Subcutaneous adipose tissue (kg) 
Marin 1993 [58]  Gel   9 mo  -1.2  0.5  -1.7 
Allan 2008 [57]  Patch  12 mo  -0.1  0.0  -0.1 
Subcutaneous adipose tissue (cm
3) 
Svartberg 2008 [71]  Inj TU  12 mo  -49  -10  -39 
Total adipose tissue (cm
3) 
Svartberg 2008 [71]  Inj TU  12 mo  -86  -27  -59 
Right leg fat (kg) 
Page 2005 [69]  TE  36 mo  -0.9  0.1  -1.0 
Percentage total body fat (%) 
Sih 1997 [84]  TC  12 mo  -1.9  19.3  -21.2 136    Current Diabetes Reviews, 2012, Vol. 8, No. 2  Saad et al. 
 
Table 1. contd… 
 
Reference / Parameter  Preparation 
Treatment 
Duration 
Change T  Change Plc  Net Change 
Boyanov 2003 [64]  Oral TU   3 mo  -3  -0.1  -2.9 
Crawford 2003 [65]  Mixed esters  12 mo  -10.9  3.4  -14.3 
Steidle 2003 [66]  Gel  3 mo  -1.2  -0.2  -1.0 
Steidle 2003 [66]  Patch   3 mo  -0.5  -0.2  -0.3 
Casaburi 2004 [67] (no tr.)  TE   10 wk  -6  -0.1  -5.9 
Casaburi 2004 [67] (training)  TE  10 wk  -9.4  -2.2  -7.2 
Page 2005 [69]  TE  36 mo  -17.0  1.0  -18.0 
Kapoor 2007 [51]  Mixed esters  3 mo  -3.7  -1.5  -2.2 
Kapoor 2006 [70]  Mixed esters  3 mo  -3.0  -1.8  -1.2 
Svartberg 2008 [71]  Inj TU  12 mo  -18.9  -1.9  -17.0 
Allan 2008 [57]  Patch  12 mo  -2.9  0.4  -3.3 
Emmelot-Vonk 2008 [10]  Oral TU   6 mo  -4.7  0.0  -4.7 
Aversa 2010 [85]  Inj TU  24 mo  -18.5  0.5  -19 
Aversa 2010 [87]  Inj TU  12 mo  -18.4  0.6  -19.0 
Waist circumference (cm) 
Marin 1993 [58]  Gel   9 mo  -2.5  -0.6  -1.9 
Kapoor 2007 [51]  Mixed esters  3 mo  -2.0  0.1  -2.1 
Kapoor 2006 [70]  Mixed esters  3 mo  -1.6  N/A  N/A 
Svartberg 2008 [71]  Inj TU  12 mo  -3.0  -1.0  -2.0 
Heufelder 2009 [12]  Gel  12 mo  -14.6  -6.7  -7.9 
Aversa 2010 [85]  Inj TU  24 mo  -8.5  -0.5  -8.0 
Kalinchenko 2010 [74]  Inj TU  30 wk  -5.8  -1.5  -4.3 
Aversa 2010 [87]  Inj TU  12 mo  -8.7  1.1  -9.7 
Gel: testosterone gel  
Patch: testosterone patch 
TE: parenteral testosterone enanthate 
Oral TU: oral testosterone undecanoate 
Mixed esters: mixed parenteral testosterone esters 
Inj TU: parenteral testosterone undecanoate 
TC: parenteral testosterone cypionate 
 
also of adiponectin was found upon T administration to men 
with TD with or without T2DM [51]. T therapy reduced 
waist circumference (-1.63 ± 0.71 cm, p = 0.03) and 
waist/hip ratio (-0.03 ± 0.01, p = 0.01), improved IR and 
glycemic control in men with TD and T2DM [51, 70]. T 
treatment reduced fat mass (-5.4±2.4 kg) and abdominal adi-
pose tissue and increased fat-free mass in a one-year study 
[71] (Fig. 1). T treatment selectively lessened visceral fat 
accumulation without change in total body fat mass and in-
creased total body fat free mass and total body and thigh 
skeletal muscle mass in a study of men over 55 years over 52 
weeks [57]. Interestingly, a monthly cycled T regimen using 
half the T dose compared to the standard care of continuous 
therapy, improved body composition and increased muscle 
strength similarly to continuous T [72]. 
A study of T administration in 207 men over 6 months 
reported an increase in lean body mass and a decrease in fat 
mass (-1.3 kg; range -1.8 to 0.8) and a decrease in fat mass 
percentage (-1.7%, range -2.1—1.1) [10]. The above studies 
have been conducted in men with low serum T but there are 
two studies demonstrating a beneficial effect of T admini-
stration in men whose serum T is not subnormal but in the 
low range of normal [57, 58]. In a double blind, placebo-
controlled study over a 6-month period, transdermal T treat-
ment was associated with beneficial effects on insulin resis-
tance, total and LDL-cholesterol, lipoprotein(a), and sexual 
health in hypogonadal men with type 2 diabetes and/or MetS 
[73]. 
Characteristics of the obese person co-determine the ef-
fects of T administration. BMI was significantly associated  Obesity and Testosterone  Current Diabetes Reviews, 2012, Vol. 8, No. 2    137 
 
Table 2. Changes in Lean Mass Upon Testosterone (T) Treatment Versus Placebo (Plc). 
 
Reference / Parameter  Preparation 
Treatment 
Duration 
Change T  Change Plc  Net Change 
Total lean mass (kg) 
Marin 1993 [58]  Gel   9 mo  1.5  0.2  1.3 
Snyder 1999 [59]  Patch   36 mo  2.1  -0.3  2.4 
Kenny 2001 [62]  Patch   12 mo  1.0  0.2  0.8 
Crawford 2003 [65]  Mixed esters  12 mo  1.8  -0.5  2.3 
Ferrando 2003 [63]  TE  6 mo  4.2  -2  6.2 
Steidle 2003 [66]  Gel  3 mo  1.7  0.6  1.1 
Steidle 2003 [66]  Patch   3 mo  0.9  0.6  0.3 
Wittert 2003 [61]  Oral TU   12 mo  1.0  -1.0  2.0 
Casaburi 2004 [67] (no training)  TE   10 wk  2.3  -0.21  2.51 
Casaburi 2004 [67] (training)  TE  10 wk  3.29  0.2  3.09 
Page 2005 [69]  TE  36 mo  3.7  0.0  3.7 
Kapoor 2006 [70]  Mixed esters  3 mo  1.23  0.67  0.56 
Svartberg 2008 [71]  Inj TU  12 mo  4.2  0.4  3.8 
Allan 2008 [57]  Patch  12 mo  0.8  -0.3  1.1 
Emmelot-Vonk 2008 [10]  Oral TU   6 mo  1.1  -0.3  1.4 
Srinivas-Shankar 2010 [68]  Gel   6 mo  1.1  -0.2  1.3 
Aversa 2010 [85]  Inj TU  24 mo  4.8  -0.1  4.9 
Aversa 2010 [87]  Inj TU  12 mo  4.2  -0.6  4.8 
Gel: testosterone gel  
Patch : testosterone patch 
TE: parenteral testoterone enanthate 
Oral TU: oral testoterone undecanoate 
Mixed esters: mixed parenteral testoterone esters 
Inj TU: parenteral testoterone undecanoate 
 
with the benefit of T treatment on all variables measured 
except on C-reactive protein [74, 75]. Waist circumference 
also showed these associations, but BMI appeared to be a 
slightly stronger predictor than baseline waist circumference 
(Fig. 3), it is of utmost interest to indicate that in all three 
anthropometric parameters there is a progressive improve-
ment in the group of men treated with T. In contrast, the pla-
cebo group shows initial improvement after 18 weeks which 
returns toward baseline levels only 12 weeks later, indicating 
the transient effect of the physician’s advice to improve life 
style [74]. 
TESTOSTERONE, DIET AND EXERCISE AND 
WEIGHT LOSS  
The successes of interventions to achieve long-term 
weight loss in obese men are conflicting and most often dis-
appointing. In a systematic review and meta-analysis of sub-
jects of 60 years or above a modest but significant weight 
loss of 3.0 kg [95% confidence interval (CI) 5.1-0.9] at 1 
year was noted [76]. Another very thorough review reported 
weight loss in various populations of between 0.04 and 4.9 
kg [77]. Total cholesterol did not show a significant change: 
-0.36 mmol/l (95% CI -0.75 to 0.04). There was no signifi-
cant change in high-density lipoprotein, low-density lipopro-
tein or triglycerides. In one study, recurrence of hypertension 
or cardiovascular events was significantly reduced (hazard 
ratio 0.65, 95% CI 0.50-0.85). Six-minute walk test did not 
significantly change in one study. Health-related quality of 
life significantly improved in one study [70] but did not im-
prove in a second study [73]. The expectations for weight 
loss in overweight patients are several hundred percent 
higher than achieved in real life. All these studies did not 
include baseline T levels as an inclusion/exclusion criterium 
neither variation from baseline as an endpoint. 
Weight loss interventions without changes in aerobic ca-
pacity do not appear to enhance muscle oxidative capacity in 
obesity. There is an increased capacity of intracellular fatty 
acid transport in skeletal muscle cells in the physiological 
adaptations of fat metabolism to energy restriction in obe-
sity. In obesity-related IR, the metabolic capacity of skeletal 
muscle appears to be organized towards fat esterification 
rather than oxidation and dietary-induced weight loss does 138    Current Diabetes Reviews, 2012, Vol. 8, No. 2  Saad et al. 
 
not correct this disposition [78]. Mitochondrial electron 
transport chain (ETC) activity in skeletal muscle in previ-
ously sedentary obese men and women was substantially 
improved by an intervention of moderate weight loss and 
moderate intensity of physical activity. These biochemical 
changes in skeletal muscle mitochondria occurred in con-
junction with improvement in substrate metabolism and in-
sulin sensitivity in muscle. Interestingly, the increase in ETC 
activity in skeletal muscle in these previously sedentary 
obese men and women was greater than that of mitochon-
drial DNA content, signifying a more pronounced effect on 
functional capacity of mitochondria than on proliferation 
[78, 79]. Diet-induced weight loss significantly decreases 
muscle mass in older adults. However, the addition of mod-
erate aerobic exercise to intentional weight loss attenuates 
the loss of muscle mass [78]. In a systematic review assess-
ing the effects of energy restriction and exercise on fat-free 
mass in overweight and obese middle-aged and older adults, 
it was concluded that exercise is an effective tool in men and 
postmenopausal women aged  50 years, with a BMI greater 
than 25 kg/m
2 to preserve fat free mass and to combat sarco-
penic obesity after moderate weight loss induced by energy 
restriction [80]. A low-glycemic diet with exercise may pro-
vide an alternative and more effective treatment for IR in 
older obese adults [81, 82]. Exercise training improves rest-
ing substrate oxidation and creates a metabolic milieu that 
appears to promote lipid utilization in skeletal muscle, thus 
facilitating a reversal of IR [82, 83]. Restoring T to physio-
logical values in men with TD results in loss of fat mass and 
increase in lean body mass. As a result, the loss of body 
weight may be quantitatively less impressive. A meta-
analysis of randomized controlled trials evaluating the ef-
fects of T administration to middle-aged and ageing men on 
body composition showed a reduction of 1.6 kg (CI: 2.5--
0.6) of total body fat corresponding to -6.2% (CI: 9.2--3.3) 
variation of initial body fat, an increase in fat free mass of 
1.6 kg (CI: 0.6--2.6), corresponding to +2.7% (CI: 1.1--4.4) 
increase over baseline and no change in body weight [83]. In 
studies with a similar design comparable results were re-
ported with regard to total body fat [64-67, 70, 84]. In a pla-
cebo-controlled study using long-acting T undecanoate injec-
tions, the reduction of fat mass was 5.4 kg with an increase 
of lean mass of 4.2 kg [71]. T also reduced total cholesterol 
by 0.23 mmol/l (CI: -0.37 to -0.10), especially in men with 
lower baseline T concentrations, with no change in low-
density lipoprotein (LDL)-cholesterol. Low serum T levels 
are associated with an adverse metabolic profile including 
IR, and there is evidence for a unifying mechanism that low 
T levels and impaired mitochondrial function promote IR in 
men [41]. Indeed, administration of T to men with TD im-
proves insulin sensitivity. A study in men with TD and 
T2DM showed that T replacement also improves glycemic 
control although this study was non-blinded. In another re-
cent study of T administration in men with MetS and lower-
than-normal T levels a reduction in waist circumference, 
visceral fat mass, and improvement in Homeostasis Model of 
Assessment - Insulin Resistance (HOMA-IR) without 
changes in body mass index was observed [70, 85]. 
T may exert a dual effect on metabolism with an acute 
improvement in insulin sensitivity that occurs rapidly within 
a few days to few weeks of treatment, and before loss of fat 
mass becomes evident; and a prolonged effect achieved 
when a significant reduction of total and visceral body fat 
occurs [86, 87]. Given the fact that T replacement will pro-
mote a more active life-style, the rapid effects are needed to 
prepare the body to greater energy expenditure. In fact, phy-
sicians treating obesity should be aware of the risks of rec-
ommending physical exercise or intensive training to obese 
men with TD. In view of the importance of T in bone and 
muscles homeostasis, it is evident that obese men should 
receive androgen replacement prior to commencing physical 
training [88]. 
 
Fig. (3). Absolute changes in anthropometric parameters in the double-blind, placebo-controlled Moscow study in 184 men with metabolic 
syndrome. Adapted from reference [74]. 
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SAFETY OF TESTOSTERONE THERAPY  
Studies to prove long-term safety of T have not been per-
formed and will not be performed shortly because of logis-
tics and budgetary problems. Physicians hesitate to prescribe 
T to men over the age of 50 years fearing it will induce PCa. 
Recent findings have placed such fear in a more rational per-
spective. T treatment in men [89] did not exacerbate voiding 
symptoms due to benign prostatic hyperplasia. The occur-
rence of PCa after T administration in (elderly) men has been 
reported, mostly in case reports [90]. By contrast, a host of 
studies, using various designs and T formulations, over peri-
ods ranging from several months to 15 years, in men with a 
wide range of ages, have not revealed an increased risk of 
PCa [91]. A meta-analysis found that T treatment in older 
men compared to placebo was not associated with a signifi-
cantly higher risk of detection of PCa [89], although the fre-
quency of prostate biopsies was much higher in the T-treated 
group than in the placebo group [89]. There is no convincing 
evidence that T is the main factor in the development or pro-
gression of PCa in men [92, 93]. But as indicated above, the 
definitive studies to define the safety of T have not been car-
ried out. Guidelines for monitoring have been developed 
which, if rigorously applied, render T treatment to be a safe 
therapy in men without (a prior history of) PCa.  
T produces a dose dependent effect on hemoglobin and 
hematocrit values [94], apparent in a number of studies , and 
remarkably, this effect is more pronounced in older men [95-
97]. Though an elevated hematocrit is associated with stroke, 
and coronary heart disease, a relation between increased he-
matocrit as a result of androgen supplementation as such and 
an increased risk for stroke or any cardiovascular event in 
general has not been demonstrated by large meta-analyses of 
placebo-controlled trials of T administration to (elderly) men 
[14, 89]. Polycythemia is a manageable risk of androgen 
administration when hemoglobin levels and hematocrit are 
monitored and the dose of T is adjusted. 
Until a decade ago, it was a widely held belief that an-
drogens have an atherogenic effect and thus led to CVD, and 
androgen therapy was regarded a risk of developing CVD. 
Over the last decade several studies have examined the rela-
tionship of androgens with CVD and concluded that it is no 
longer tenable to regard T as a culprit in the etiology of CVD 
[98, 99]. The study of Basaria et al. [100] has drawn new 
attention to the potential cardiovascular risks of T admini-
stration to elderly frail men, but the study has also been criti-
cally examined for a number of potential biases, addressed in 
a recent review [101].  
T therapy in elderly men may be viewed as a responsible 
practice provided certain guidelines produced by profes-
sional scientific and clinical organizations are followed with 
regard to T therapy in elderly men [16]. This consensus is 
based on expert opinion and, therefore, the need for longer-
term safety studies remains urgent.  
FUTURE PERSPECTIVE 
Obesity is a growing health problem worldwide. It im-
pairs health and thus quality of life. Treatment is far from 
simple. Obesity produces a host of metabolic changes at the 
molecular and cellular levels in a host of tissues, including 
the skeletal muscle. These metabolic changes bring about 
programmed cell death and increased inflammatory markers 
and produce a vicious cycle that contributes to TD and obe-
sity (Fig. 4). The link between IR, obesity and MetS and the 
onset of T2DM is well established, however the exact cellu-
lar mechanisms remain under extensive investigations. 
Diet treatment is only marginally successful and leads to 
loss of muscle mass, which may be prevented by combining 
diet with exercise. Although treatment of obesity by lifestyle 
interventions in high risk patients, especially those at high 
risk for T2DM is highly recommended, it is usually little 
successful and of limited clinical benefit. Pharmacological 
treatment is only modestly successful and not without car-
 
Fig. (4). The vicious cycle of testosterone deficiency and obesity. Adapted from Jones TH. Pract Diab Int 2007; 24(5): 269-277. 
Insulin
resistance
Hypothalamo-
Pituitary axis
-ve
Resistance
-ve
Adipose
tissue
 LH pulse
amplitude
-ve
Testis
Oestradiol
TNF-
IL-6
Leptin
Aromatase
-ve
-ve
 Triglyceride
uptake  Testosterone
 Activity of
Lipoprotein lipase
 Adipocytes140    Current Diabetes Reviews, 2012, Vol. 8, No. 2  Saad et al. 
 
diovascular side effects [102]. A substantial number of obese 
men with T2DM exhibit reduced androgen levels. In these 
subjects, T treatment reduces fat mass and increases lean 
body mass and very likely also improves insulin sensitivity. 
T treatment improves muscle mass, reduces fat mass and 
muscle strength and physical performance. In addition, T 
increases motivation and decreases fatigue [103] and may 
therefore enable men to better adhere to an exercise pro-
gramme. Thus, T may represent a useful tool in managing 
obesity in hypogonadal men when used together with diet 
and exercise.  
There is as yet a lack of definition of a level of testoster-
one for initiating safe supplementation therapy in patients 
who are obese but do not suffer from testosterone deficiency 
symptoms. It is of note that in aging men, psychosomatic 
complaints and metabolic risk relate to levels of testosterone 
in a symptom-specific manner; some symptoms appear 
above the lower cut-off levels for the reference range of T 
[104]. But, until more specific information is available, T 
treatment should be limited to men with established bio-
chemical criteria of TD [15, 16]. A recent study provided 
quantitative information. The mean (SD), median (quartile), 
and 2.5th percentile values were 723.8 (221.1), 698.7 
(296.5), and 348.3 ng/dl for total T and 141. 8 (45.0), 134.0 
(60.0), and 70.0 pg/ml for FT, respectively, clinically vali-
dated by the fact that in all three samples, men with low TT 
and FT were more likely to have slow walking speed, diffi-
culty climbing stairs, or frailty and diabetes [15]. But benefi-
cial effects on features of the metabolic syndrome have been 
encountered in men with serum T levels above the lower 
limit of reference values [57, 105].  
T treatment has positive effects on a number of parame-
ters of cardiovascular health, such as serum LDL-cholesterol, 
blood pressure and heart rate [98]. Physicians managing 
overweight patients and its sequels (T2DM, CVD) are either 
unfamiliar or unaware of the physiology and patho-
physiology of TD and its impact on body composition, the 
potential of T treatment in men with MetS and its sequels is 
not seriously considered as an option. Although comparison 
studies are lacking, the magnitude of changes obtained with 
T replacement therapy appear superior (or at least as effec-
tive as) most drugs used to reduce excess fat mass. A signifi-
cant aspect of treating men with TD is the mood-elevating 
action of T in men with MetS who are often depressed and 
dysphoric. This aspect may bolster motivation to lose weight 
by adhering to a regimen of diet and exercise. Finally, rec-
ommending exercise to men with TD, for weight reduction, 
may expose these patients to severe risks [88]. To establish T 
therapy as a legitimate medical tool in the management of 
obesity in men with TD, more specific studies will be re-
quired by the regulatory agencies. These studies should con-
vincingly demonstrate that abdominal obesity and MetS are 
ameliorated by normalizing T levels in hypogonadal men. 
Such studies should be up to the level of at least phase three 
to assess the efficacy with more narrow confidence intervals 
and to provide long-term safety data. 
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LIST OF ABBREVIATIONS 
ADT  =  Androgen Deprivation Treatment  
BMI  =  Body mass Index  
CI =  Confidence  Interval 
CVD =  Cardiovascular  Disease 
ED =  Endothelial  Dysfunction 
ETC =  Electron  Transport  Chain 
FA =  Fatty  Acids 
HbA1c  =  Glycated  Hemoglobin 
IL-6  =  Interleukin 6  
IR =  Insulin  Resistance 
LH =  Luteinizing  Hormone   
MetS =  Metabolic  Syndrome 
MMAS  =  Massachusetts Male Aging Study  
MRFIT  =  Multiple Risk Factor Intervention Trial 
NHANES  III  =  Third National Health and Nutrition 
Survey 
PCa  =  Prostate Cancer  
SHBG  =  Sex Hormone Binding Globulin 
T =  Testosterone   
TD  =  Testosterone Deficiency  
TNF- =  Tumor
 Necrosis Factor-alpha  
T2DM  =  Diabetes Mellitus Type 2 
WC =  Waist  Circumference 
WHR =  Waist/Hip  Ratio 
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